Drugs / LY-M001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06528080 | Aug 2024 → May 2027 expected | Gaucher disease | Shanghai Jiao Tong University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06818838 | Jul 2024 → Jul 2027 expected | Gaucher disease type I | Lingyi Biotech Co., Ltd. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06162338 | Nov 2023 → Dec 2026 expected | Gaucher disease type I | He Huang | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY-M001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06162338 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “LY-M001 Injection is an rAAV8 vector gene therapy product.” NCT06818838 ↗ |
| Route | Intravenous | “LY-M001 injection is administered by intravenous infusion” NCT06162338 ↗ |